Magnetar Financial’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Magnetar Financial’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-453,622	Closed	-$52.5M	–	612
2023 Q3	$52.5M	Sell	453,622 -155,535	-26%	-$16.7M	1.34%	23
2023 Q2	$62.7M	Sell	609,157 -126,296	-17%	-$13.3M	1.37%	21
2023 Q1	$80.3M	Sell	735,453 -47,612	-6%	-$5.26M	1.57%	13
2022 Q4	$89.1M	Buy	+783,065	New	+$65M	1.51%	7
2022 Q3	–	Sell	-342,941	Closed	-$27.4M	–	2046
2022 Q2	$27.4M	Buy	342,941 +46,264	+16%	+$4.38M	0.28%	54
2022 Q1	$31.2M	Buy	296,677 +130,916	+79%	+$12.8M	0.33%	49
2021 Q4	$17.9M	Buy	+165,761	New	+$18.1M	0.18%	125
2021 Q1	–	Sell	-106,012	Closed	-$7.75M	–	1356
2020 Q4	$7.75M	Buy	+106,012	New	+$7.88M	0.11%	196

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Magnetar Financial's HZNP Position: Q4 2023 in Review

Magnetar Financial sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 453,622 shares — an estimated $52.5M sold.

Magnetar Financial first reported a position in HZNP in Q4 2020 and held it in 8 quarters. The position peaked at $89.1M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Magnetar Financial reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Magnetar Financial sold 453,622 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $52.5M.
Magnetar Financial first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 8 quarters.
Magnetar Financial's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $89.1M in Q4 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Magnetar Financial's 13F filing for Q4 2023, filed 13 Feb 2024.